The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move that strengthens the long-term oncology growth strategy for major pharmaceutical players, Gilead Sciences has received a significant regulatory boost in Europe. An EMA committee adopted a positive opinion backing the use of Trodelvy in combination with Merck's Keytruda as a first-line treatment for patients with advanced triple-negative breast cancer. This recommendation is based on robust Phase 3 clinical trial data, positioning the combination therapy for final regulatory approval in the European Union.
Per market data, GILD shares closed at $132.73 on July 29, 2026, while MRK shares closed at $131.82 on July 28, 2026. The collaboration between Gilead and Merck highlights the strategic importance of combination therapies in the oncology sector, with Trodelvy serving as a central asset in Gilead's pipeline. Investors are closely watching how the company manages R&D costs associated with these advanced programs while attempting to sustain overall margins.
Traders should watch for support levels on GILD near its recent daily low of $132.57, while MRK faces potential resistance at its daily high of $135.05. Following this positive regulatory milestone, the next catalysts include the formal final approval decision from the European Commission and Gilead's upcoming earnings report in early August, which will provide clarity on oncology's contribution to the company's total revenue.